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The Challenges of Improving Treatments
for Depression
In the past few decades substantial progress has been
made in the research and development of treatments for
major depression. Many different types of medications
and psychotherapy are currently available and rigorous
studies have shown that antidepressants are more ef-
fective than placebo,1 and several types of psychothera-
pies are more effective than waiting list or other
controls.2 These findings suggest that many patients
with depression can be successfully treated. Based on
these significant and positive effects, many of these
treatments are included in treatment guidelines and are
widely used in clinical practice. However, not all pa-
tients with depression recover with available treat-
ments and several important challenges need to be re-
solved to improve existing treatments and to increase
the number of patients who benefit from them.
Spontaneous Recovery and Placebo Effects
An important challenge is the high rates of spontane-
ous response and placebo effects. More than half of pa-
tients who receive antidepressants or psychotherapy re-
spond to treatment. However, response rates are also
high when patients receive placebo or no treatment.
In a meta-analysis that included 44 240 patients from
177 studies, 54% of patients responded to antidepres-
sants, whereas 38% responded to placebo.3 Compa-
rable numbers have been reported for psychothera-
pies with response rates of 54% compared with response
rates of 41% across control conditions.4 Patients with
depression who do not seek care show comparable
response rates. These findings differ when other out-
comes, such as remission or significant clinical change,
are used. That does not, however, change the basic chal-
lenge that a substantial proportion of patients who im-
prove with medication or psychotherapy would have re-
covered without treatment or with placebo. This poses
substantial challenges for investigators and clinicians.
Individuals who respond to medication will prob-
ably continue to use them for at least several months, even
with the risk of adverse effects. Patients who respond to
psychotherapy invest many hours and make consider-
able efforts during their treatment. For a majority of pa-
tients who respond to treatment, the potential adverse
effects of medications and the time investment in psy-
chotherapy might not be necessary to get better. How-
ever, it is not possible yet to predict which patients will re-
cover spontaneously or will respond to placebo, although
innovative machine learning techniques and other bio-
logical markers may be helpful in the future.
Spontaneous recovery also complicates the valid-
ity of clinical knowledge as well as research about treat-
ments. Because many patients recover while receiving
treatment, clinicians and patients are inclined to think
that the treatment is what made them better. How-
ever, because many patients also would have recov-
ered without treatment, clinical judgements are not nec-
essarily related to treatment effect.
Nonresponse
In contrast to response to drug or placebo, a consider-
able group of patients are difficult to treat or do not re-
spond to treatment. Although patients may respond to
another drug after failure to respond to an initially pre-
scribed drug, the chance of successful response is al-
most halved with every new treatment tried.5 Even af-
ter trying several different treatments, a substantial
proportion of patients do not respond.
One estimate suggests that approxi-
mately 30% of patients with depres-
sive disorders have a chronic course with
limited response to treatment.6
Another challenge is that the ef-
fects of treatment are probably overes-
timated. The relapse rates for patients
who respond are very high (estimated at
about 50% over 2 years),7 there is limited evidence for
long-term effectiveness, and there are the problems of
publication bias, sponsorship bias, and other sources of
bias. Clinicians may have an optimistic view that these
problems have little influence on outcomes or have a
pessimistic view that no relevant treatment effect re-
mains. In reality, the extent to which these factors affect
outcomes is unknown.
How to Improve Treatments?
Worldwide, an estimated 330 million people have de-
pression, which is linked with considerably diminished
role functioning and quality of life, medical comorbid-
ity, excess mortality, and high economic costs.8 Thus, ad-
dressing current therapeutic challenges and improving
available treatments are critically important, regard-
less of the true effects of these treatments. How can this
be done?
Additional research on the causes and etiological
processes leading to depression is needed. The focus
should be on which patients will respond to treatment,
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Nevertheless, for patients with depression
many do not benefit from treatment,
and some only partially benefit or only
experience short-term improvement.
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targeted treatments for specific groups of patients. This may result
in new approaches for preventing depression. However, this will take
time and long-term investments.
A straightforward approach in the short-term is to develop treat-
ments that are more effective than the current ones in acute phase
depression. However, many drugs and psychotherapies have been de-
veloped over the past decades, and there is little evidence that one
drug or psychotherapy is substantially more effective than the oth-
ers. It is therefore unlikely that newly developed drugs and therapies
will be substantially better than the ones that are currently available.
A potentially viable approach with respect to spontaneous
recovery is to minimize treatments and reduce unnecessary re-
source use because many patients with depression will recover spon-
taneously, regardless of treatment. Clinicians already use a “watch-
ful waiting” approach, by encouraging patients to wait before starting
a treatment. Another option is to offer internet-based or other self-
help interventions that involve no or minimal support from profes-
sionals, preferably in stepped-care models allowing patients who
do not respond to these interventions to step up to more intensive
treatment. Considerable evidence indicates that these internet-
based interventions are effective and require less resources.9
Another option may be to clearly explain to patients what the chance
for recovery is from treatment, from placebo, or from no treat-
ment. This may stimulate patients with milder disorders to wait
before starting treatment, whereas patients with severe disorders
will probably prefer to initiate treatment.
There are also several priorities for patients with depression who
have high relapse rates or those who do not respond to treatments.
One important priority is to further examine relapse prevention. In rou-
tine practice, this often consists of maintenance treatment with drugs.
However, convincing evidence indicates that psychological interven-
tions can reduce relapse rates considerably, although these interven-
tions are seldom implemented in routine care.
Another priority is to increase research on the treatment of
chronic and resistant depression. Fortunately, these conditions are
increasingly the focus of drug trials, and some promising new medi-
cations are being tested, such as ketamine.10 However, few psycho-
logical treatments are available that are specifically designed for
chronic depression. The development of such therapies should have
more priority than developing new therapies for acute depression
that almost certainly will show comparable effects as already exist-
ing treatments.
Answering the Challenge
Evidence-based treatments can make a substantial difference in the
lives of many patients. Nevertheless, for patients with depression
many do not benefit from treatment, and some only partially ben-
efit or only experience short-term improvement. Furthermore, a con-
siderable group of treated patients would have also recovered with-
out treatment. The group of patients in between these extremes are
the ones who currently benefit from available treatments, but they
are still a minority of all patients. Because of the public health ef-
fects of depression and the enormous related adverse effects on the
quality of life of patients, it should be a priority to search for meth-
ods to increase the number of patients who benefit from treat-
ment and in this way reduce the burden of depression.
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